Dennis K. Stone

American Society for Clinical Investigation engages as a medical honor society. It focuses on physician-scientists in research, clinical care, and medical education. The company was founded by Samuel J. Meltzer in 1908 and is headquartered in Ann Arbor, MI.

The Association of American Physicians operates as an American association of physicians. The non-profit company is based in Tucson, AZ. The company was founded by Charles Lee.

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.

Part of MacroGenics, Inc., Eliance Biotechnology, Inc. is a company that researches and develops vaccines. The company is based in Dallas, TX. The company was founded by Stephen Albert Johnston. Eliance Biotechnology was acquired by MacroGenics, Inc. on June 07, 2002.

Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO.

miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO.

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Texas Emerging Technology Fund provides technology investment fund. It offers funds in the form of equity, convertible debt, grants, and other forms of contribution or investment. The company was founded in 2005 and is headquartered in College Station, TX.